The future of psychopharmacological enhancements: Expectations and policies

Neuroethics

Volumn 2, Issue 2, 2009, Pages 75-87

  Schermer, Maartje ^a   Bolt, Ineke ^a,b   De Jongh, Reinoud ^c   Olivier, Berend ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Enhancement; Policy; Psychopharmacology

Indexed keywords

MODAFINIL; NOOTROPIC AGENT; PROPRANOLOL;

ATTENTION DEFICIT DISORDER; COGNITION; DRUG EFFICACY; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; MEDICAL ETHICS; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SLEEP DISORDER;

EID: 70350783936     PISSN: 18745490     EISSN: 18745504     Source Type: Journal    
DOI: 10.1007/s12152-009-9032-1     Document Type: Review

References (63)

1. Illes, J (ed). 2006. Neuroethics. Defining issues in theory, practice and policy. Oxford: Oxford University Press.
2. Glannon, W. 2007. Bioethics and the brain. Oxford: Oxford University Press.
3. Levy, N. 2007. Neuroethics. Challenges for the 21st century. Cambridge: Cambridge University Press.
4. Gazzaniga, M.S. 2005. The ethical brain. Washington DC: Dana Press.
5. Parens, E. 1998. Enhancing human traits: ethical and social implications. Washington DC: Georgetown University Press.
6. President's Council on Bioethics. 2003. Beyond therapy. Biotechnology and the pursuit of happiness. New York: Dana Press.
7. Buchanan, A., D.W. Brock, N. Daniels, and D. Wikler. 2000. From chance to choice. Genetics and justice. Cambridge: Cambridge University Press.
8. Harris, J. 2007. Enhancing Evolution. The ethical case for making better people. Princeton University Press.
9. P.D. Kramer 2000 The Valorization of Sadness: Alienation and the Melancholic Temperament Hastings Center Report 30 2 13 18 10.2307/3528307
10. C. Elliott 2000 Pursued by happiness and beaten senseless. Prozac and the American dream Hastings Center Report 30 2 7 12 10.2307/3528306
11. L.H. Diller 1996 The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990's Hastings Center Report 26 12 18
12. S. Rose 2002 'Smart drugs': do they work? Are they ethical? Will they be legal? Nature reviews neuroscience 3 975 979 10.1038/nrn984
13. M. Farah J. Illes, et al. 2004 Neurocognitive enhancement: what can we do and what should we do? Nature reviews neuroscience 5 421 425 10.1038/nrn1390
14. M.J. Mehlman 2004 Cognition-enhancing drugs The Milbank Quarterly 82 3 483 506 10.1111/j.0887-378X.2004.00319.x
15. M. Schermer 2007 Brave New World versus Island. Utopian and dystopian views on psychopharmacology Medicine, Health Care and Philosophy 10 2 119 128 10.1007/s11019-007-9059-1
16. N. Bostrom 2003 Human genetic enhancements: a transhumanist perspective Journal of Value Inquiry 37 4 493 506 10.1023/B:INQU.0000019037.67783.d5
17. J. Savulescu 2006 Justice, fairness, and enhancement Annals of the New York Academy of Sciences 1093 321 338 10.1196/annals.1382.021
18. Fukuyama, F. 2002. Our posthuman future. Consequences of the biotechnology revolution. New York: Farrar, Strauss and Giroux.
19. M.J. Sandel 2004 The case against perfection Atlantic Monthly 293 251 263
20. Roco, M.C., and W.S. Bainbridge. 2002. Converging Technologies for Improving Human Performance. Arlington, Virginia: National Science Foundation.
21. N. Brown 2003 Hope against hype-accountability in biopasts, presents and futures Science Studies 16 2 3 21
22. A. Nordmann 2007 If and Then: a Critique of Speculative NanoEthics Nanoethics 1 1 31 46 10.1007/s11569-007-0007-6
23. J. Keulartz M. Schermer M. Korthals T. Swierstra 2004 Ethics in a technological culture. A programmatic proposal for a pragmatist approach Science, Technology and Human Values 29 1 3 29 10.1177/0162243903259188
24. R. de Jongh I. Bolt M. Schermer B. Olivier 2008 Botox for the brain. Pharmacological enhancement of cognition, mood and personality traits Neuroscience and Biobehavioral Reviews 32 4 760 776 10.1016/j.neubiorev.2007.12. 001
25. D.C. Randall N.L. Fleck, et al. 2004 The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers Pharmacol Biochem Behav 77 547 55 10.1016/j.pbb.2003.12.016
26. N.J. Wesensten G. Belenky 2002 Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine Psychopharmacology (Berl) 159 238 247 10.1007/s002130100916
27. R. Elliott B.J. Sahakian, et al. 1997 Effects of methylphenidate on spatial working memory and planning in healthy young adults Psychopharmacology (Berl) 131 196 206 10.1007/s002130050284
28. E. Juengst R. Binstock, et al. 2003 Biogerontology, 'anti-aging medicine', and the challenges of human enhancement Hastings Center Report 33 21 30 10.2307/3528377
29. B. Sahakian S. Morein-Zamir 2007 Professor's little helper Nature 450 1157 1159 10.1038/4501157a
30. N. Bostrom 2008 Drugs can be used to treat more than diseases Nature 451 520 10.1038/451520b
31. K. Davis 2007 Rethinking "Normal" The Hastings Center Report May-June 44 47
32. R. Moynihan I. Heath, et al. 2002 Selling sickness: the pharmaceutical industry and disease mongering British Medical Journal 324 886 891 10.1136/bmj.324.7342.886
33. P. Conrad 2005 The Shifting Engines of Medicalization Journal of Health and Social Behavior 46 3 14
34. P. Conrad D. Potter 2000 From Hyperactive Children to ADHD Adults: Observations on the Expansion of Medical Categories Social Problems 47 4 559 582 10.1525/sp.2000.47.4.03x0308v
35. S.E. McCabe C.J. Teter H. Wechsler 2005 Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey Addiction 100 96 106 10.1111/j.1360-0443.2005.00944.x
36. C. Teter S. McCabe, et al. 2006 Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration Pharmacotherapy 26 1501 1510 10.1592/phco.26.10.1501
37. B. Prudhomme White K. Becker-Blease K. Grace Bishop 2006 Stimulant medication use, misuse and abuse in an undergraduate and graduate student sample Journal of American College Health 5 261 8 10.3200/JACH.54.5.261-268
38. van der Poel, A., K. Lens, P. Vuijk, and R. Vet. 2007. Oneigenlijk gebruik van medicijnen door jongeren. [Abuse of medication by adolescents]. Rotterdam: Instituut voor VerslavingsOnderzoek.
39. http://www.nieuwsblad.be/Article/Detail.aspx?articleid=EK1CQJM5 (accessed 15 sept 2008) http://www.grenswetenschap.nl/permalink.asp?grens=1753 (accessed 15 sept 2008)
40. B. Maher 2008 Poll results: look who's doping Nature 452 674 5 10.1038/452674a
41. M. Schermer 2008 On the argument that enhancement is cheating Journal of Medical Ethics 34 85 88 10.1136/jme.2006.019646
42. A. Ravelingien A. Sandberg 2008 Sleep better than medicine? Ethical issues related to 'wake enhancement' Journal of Medical Ethics 34 9 e9 10.1136/jme.2007.022590
43. Dehue, T. 2008. De depressie-epidemie. [The depression epidemic]. Amsterdam: Uitgeverij Augustus.
44. R. Dresser 2007 The Curious Case of Off-Label Use The Hastings Center Report May-June 9 11
45. Caspers, P.W.J., R. Gijsen, and A. Blokstra. 2007. Off-label gebruik van geneesmiddelen. Transparantiegewenst. (Off-label use of precription drugs. Transparency required). Bilthoven: RIVM.
46. B. Vastag 2004 Poised to challenge need for sleep, 'wakefullness enhancer' rouses concern JAMA 291 167 70 10.1001/jama.291.2.167
47. Synofzik, M. 2009. Ethically justified, clinically applicable criteria for physician-decision making in psychopharmacological enhancement. Neuroethics, this issue
48. Little, M.O. 1998. Cosmetic surgery, suspect norms and the ethics of complicity. In Enhancing Human Traits, ed. E. Parens, 162-176. Washington: Georgetown University Press.
49. J.M. Appel 2008 When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology Journal of Medical Ethics 34 616 18 10.1136/jme.2007.022723
50. Stein, D.J. 2008. Philosophy of psychopharmacology: a naturalist approach. Cambridge: Cambridge University Press.
51. I.D. Montoya E. Jano 2007 Online pharmacies: safety and regulatory considerations International Journal of Health Services 37 2 279 289 10.2190/1243-P8Q8-6827-H7TQ
52. J. Savulescu 2005 New breeds of humans: the moral obligation to enhance Reproductive BioMedicine Online 10 36 39
53. J. Riis J.P. Simmons G.P. Goodwin 2008 Preferences for enhancement pharmaceuticals: the reluctance to enhance fundamental traits Journal of Consumer Research 35 495 508 10.1086/588746
54. M.J. Mehlman J.W. Berg 2008 Human subject protections in biomedical enhancement research: assessing risk and benefit and obtaining informed consent Journal of Law, Medicine and Ethics 36 546 549 10.1111/j.1748-720X.2008.303.x
55. H. Greely B. Sahakian J. Harris R.C. Kessler M. Gazzaniga P. Campbell N.J. Farah 2008 Towards responsible use of cognitive-enhancing drugs by the healthy Nature 456 702 705 10.1038/456702a
56. I. Kirsch, et al. 2008 Initial severity and anti-depressant benefits: a meta-analysis of data submitted to the Food and Drug Administration PloS Medicine 5 e45 10.1371/journal.pmed.0050045 doi:10.1371/journal.pmed.0050045
57. P.B. Fontanarosa D. Rennie C.D. DeAngelis 2004 Post-marketing Surveillance-Lack of Vigilance, Lack of Trust JAMA 292 21 2647 2650 10.1001/jama.292.21.2647
58. E.H.M. Moors W.P.C. Boon R. Nahuis R.L.J. Vandeberg 2008 User-producer interactions in emerging pharmaceutical and food innovations International Journal of Innovation Management 12 3 459 487 10.1142/S1363919608001984
59. P.C. Waller S.J.W. Evans 2003 A model for the future conduct of pharmacovigilance Pharmacoepidemiology and Drug Safety 12 17 29 10.1002/pds.773
60. Broersen, S., Ziekte te koop (Disease for sale). 2009. Medisch Contact 64: 20-22.
61. E.J. Wagena P. Knipschild 2005 Do drug firms hoodwink medical journals? Or is something wrong with the contribution and integrity of declared authors J Med Ethics 31 307 10.1136/jme.2004.008433
62. S. Sismondo 2007 Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry? PLoS Medicine 4 1429 1433 10.1371/journal.pmed.0040286
63. B. Moffatt C. Elliott 2007 Ghost Marketing; pharmaceutical companies and ghostwritten journal articles Perspectives in Biology and Medicine 50 18 31 10.1353/pbm.2007.0009